Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2025/2028

Lund, Sweden — 27 May 2025 — The Annual General Meeting of Camurus on 27 May 2025, resolved – for the purpose of ensuring that the company can fulfill its commitments under the long-term incentive program for employees of the Camurus group resolved by the Annual General Meeting (Performance Share Plan 2025/2028) – on a directed share issue of no more than 240,000 redeemable and convertible series C shares. DNB Carnegie Investment Bank AB has subscribed for all 240,000 series C shares. The subscription price amounted to SEK 0.025 per share, which corresponds to the quota value of the shares.

The Annual General Meeting also resolved to authorize the Board of Directors to resolve on the repurchase of all issued series C shares by an offer directed to all holders of series C shares. Repurchase under this authorization may be made on one or several occasions until the Annual General Meeting 2026.

Today, the Board of Directors has resolved to exercise the repurchase authorization for the said purpose by repurchasing all issued series C shares against payment of approximately SEK 0.32 per share. Repurchase of the series C shares shall be effected no later than 30 June 2025, and DNB Carnegie Investment Bank AB has informed Camurus that it intends to accept the repurchase offer.

The company currently holds 240,000 own common shares and no own series C shares. Subsequently to the effected repurchase of series C shares above, all repurchased series C shares are intended to be converted to common shares, whereafter the number of own common shares will amount to 480,000.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
[email protected]

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.

The information was submitted for publication at 9.30 pm CEST on 27 May 2025.